Resonance Health Ltd. advised the launch of its latest initiative, Resonance Clinical, which aims to capitalise on the lucrative and rapidly expanding global clinical trial marketplace, especially for new drugs and therapies being developed to treat liver diseases including iron- overload disorders and NAFLD/NASH, which is estimated to affect up to 30% of the global population. This initiative builds on Resonance Health's decades-long experience providing high-quality image-analysis and clinical trial services to pharma/biotech and their clinical trial management partners, collectively referred to as clinical research organisations, or simply, CROs. Resonance Clinical intends to provide full CRO services, as well as expanded imaging CRO and central laboratory CRO services to existing, as well as new pharmaceutical and biotech customers.

Resonance Clinical, led by Program Director & Chief Scientist-Molecular Medicine, Dr. Sherif Boulos, will draw on expertise from across the Resonance Health group. These existing capabilities include PhD scientists (with biomedical and physics training), clinical researchers, trained medical laboratory scientists, and a highly experienced QA/QC team. As part of this initiative, equipment and personnel will be relocated from Murdoch University and UWA into a larger, purpose designed, dedicated Resonance Clinical laboratory at Bentley Tech Park in Perth, Western Australia.

This arrangement will deliver immediate cost-savings, provide greater autonomy, versatility and enhanced long-term security and importantly, allow Resonance Clinical to offer large numbers of high-value clinical assessments for drug trials. Presently, the Company's commercially available MRI phantom products, used to calibrate MRI machines, are manufactured at UWA and the molecular R&D program utilises labs at Murdoch University. The Company is in discussions with a variety of potential collaborators and customers regarding Resonance Clinical's enhanced service offering.

Resonance Clinical will be formally launched at the national/international AusBiotech conference on 26-28 October 2022, during which The Hon. Minister Stephen Dawson MLC, whose portfolio includes innovation and medical research, is scheduled to visit the Resonance Clinical booth.